相关临床试验
649
54 进行中
药物批准
1
批准总数
监管机构
1
监管机构数
成立时间
1983
进行中（未招募）
31
4.8%
已完成
340
52.4%
尚未招募
23
3.5%
招募中
67
10.3%
暂停
3
0.5%
终止
50
7.7%
Unknown
91
14.0%
撤回
44
6.8%
- Two Canadian clinical trials published in Nature Medicine demonstrate that fecal microbiota transplant (FMT) capsules can significantly improve cancer immunotherapy outcomes and reduce toxic side effects. - Phase II studies showed 80% response rates in lung cancer patients and 75% in melanoma patients receiving FMT plus immunotherapy, compared to 39-45% and 50-58% with immunotherapy alone, respectively. - A Phase I kidney cancer trial involving 20 patients found that customized FMT may help reduce severe colitis and diarrhea side effects that often force patients to discontinue life-sustaining immunotherapy treatment. - The advanced FMT capsules, known as LND101, are produced by Lawson Research Institute and represent a scalable approach to personalized microbiome therapy for cancer patients.
- A 12-month clinical trial involving 55 participants with Parkinson's disease dementia found that Ambroxol, a European cough medicine, was safe and well-tolerated while reaching therapeutic levels in the brain. - Psychiatric symptoms worsened in the placebo group but remained stable in those taking Ambroxol, and participants with high-risk GBA1 gene variants showed improved cognitive performance. - The blood marker GFAP, linked to brain damage, increased in the placebo group but stayed stable with Ambroxol treatment, suggesting potential brain protection. - The findings offer hope for a new treatment avenue for Parkinson's dementia, which affects about half of Parkinson's patients within 10 years of diagnosis.
